RxDoctor Payments DataLook up a doctor →

Brian Case, MD

Interventional Cardiology · Washington, DCNPI 1669733879

Payments from drug & device makers

$63,420in general payments, 2019–2025

Across 445 payments — averaging $142.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$19K
  • Acist Medical Systems, Inc.$9K
  • ZOLL Circulation Inc$9K
  • Medtronic$8K
  • Abbott$3K
  • Asahi Intecc USA, Inc.$3K
  • plus $12K from 35 others

What the payments were for

  • Consulting fees$8,44213%
  • Speaking & faculty fees$28,65545%
  • Travel & lodging$8,57214%
  • Food & beverage$17,61928%
  • Education$1330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$126,416
Medicare patients
365
Services billed
620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$59,052
EntrestoSacubitril/Valsartan11$21,879
Repatha SyringeEvolocumab14$19,532
EliquisApixaban12$17,107
FarxigaDapagliflozin Propanediol13$12,669
BrilintaTicagrelor12$10,902
Ezetimibe63$3,130
Metoprolol Succinate106$1,782
Atorvastatin Calcium124$1,222
Rosuvastatin Calcium41$1,187
Amlodipine Besylate86$466
Nifedipine ErNifedipine17$412
Carvedilol43$373
Torsemide18$367
Hydralazine Hcl28$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$213$59,05239 claims
AstraZenecaFarxiga, Brilinta$216$23,57125 claims
NovartisEntresto$551$21,87911 claims
PfizerEliquis$435$17,10712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →